Save time and get answers to complex questions with AI chat
Drugpatentwatch skyrizi biologic patent analysis?Pramlintide acetate price?What is dabrafenib mesylate msn patent issue?Patent expiry trametinib?Drugpatentwatch trametinib?
See the DrugPatentWatch profile for trogarzo
Yes. Trograzo (ibalizumab-uiyk) is administered by healthcare professionals as an intravenous (IV) infusion for the treatment of HIV-1 infection in people who have multidrug-resistant HIV that is resistant to other available therapies.[1]
The usual regimen begins with a loading dose, then continues with maintenance dosing. After the initial dose, follow-up doses are given every two weeks as IV infusions.[1]
In this context, “infusion” means IV administration through a vein via a dosing procedure performed in a clinic/infusion setting. It is not a subcutaneous injection.[1]
Because Trograzo is IV, patients typically need an infusion appointment and monitoring during administration per the prescribing information and clinic protocols.[1] Sources: [1] https://www.drugpatentwatch.com/ (Trograzo/ibalizumab-related information)
Other Questions About Trogarzo :